WSJ : Hedge Funds Extend Their Slide

Hedge Funds Extend Their Slide Hedge Funds Post Back-to-Back Monthly Declines

A bumpy trading environment is tripping up hedge funds.

Big stumbles by some star managers drove hedge funds to back-to-back monthly declines for the first time in two years, according to researcher HFR Inc.

The lackluster showing—the average hedge fund trailed benchmarks for both stocks and bonds in April—was a blow for an industry that charges more than other fund managers but pitches steady returns in both good times and bad.

Hedge funds on average dropped 0.17% in April, HFR said Wednesday, following a 0.33% decline in March. Funds hadn't turned in two consecutive losing months since April and May of 2012, HFR said.

That performance also trailed the broader stock market, where the S&P 500 rose 0.74% in April, including dividends. Many hedge funds, however, invest in markets other than stocks, and bet concurrently on some positions rising and others falling.

Brad Balter, a Boston-based adviser who helps wealthy investors choose hedge funds, said his clients increasingly are weighing whether they should continue pouring money into these highly paid managers.

"I'm not saying you should judge people in a single quarter, but there's less rope for poor performance," Mr. Balter said. He called the industry's showing in recent years for the most part "mediocre."

The latest industrywide figures come the same week a survey by the trade publication Institutional Investor's Alpha showed that the top 25 highest-earning hedge-fund managers collectively made $21 billion in 2013, an increase of more than 50% over 2012.

Most hedge funds charge some variation of the "2 and 20" model, in which the firm collects a 2% management fee and 20% of investment profits.

Some of the biggest losers among fund managers in April were those who tried to ride last year's big winners: tech stocks.

Coatue Management LLC, the $9 billion New York firm started by Philippe Laffont, a veteran of Julian Robertson's Tiger Management, slid about 4% for its second consecutive month of losses due mostly to tech-related stocks, according to people familiar with its results. Coatue is now down almost 11% for the year, and has given back more than half of its gains from 2013.

Hedge funds that bet on technology and health care as a group fell 3.7%, the steepest drop since 2008, according to HFR.

Jonathan Lennon, founder of hedge fund Pleasant Lake Partners, said it was challenging to navigate an environment in which many technology, media and telecommunications stocks are trading at "nosebleed valuations." He has maintained bets against technology and consumer stocks, which has helped $100 million Pleasant Lake gain about 12% this year.

The pain wasn't limited to tech stocks.

Paul Tudor Jones, a billionaire veteran of the industry and founder of Tudor Investment Corp., this week called the trading environment "as difficult as I've ever seen in my career." Mr. Jones' main fund is down about 4% this year, according to investor documents.

Sloane Robinson LLP, one of London's oldest hedge-fund firms, did even worse, recording a 20% yearly loss in its International fund. The fund has been hurt in part by bets against the Japanese yen, an investor said, a favorite hedge-fund trade from the past year that has hurt managers in 2014. Co-founder Hugh Sloan didn't respond to a request for comment.

But several boldfaced names in the industry shined.

William Ackman's Pershing Square L.P. hedge fund rose 7.3% last month, according to an investor update, helped by the activist's deal to back Valeant Pharmaceuticals International Inc.'s takeover attempt of wrinkle-treatment maker Allergan Inc.

Pershing Square L.P. is up 18.7% for the year through the end of April, according to the document viewed by The Wall Street Journal. The firm manages $13.7 billion overall.

Astenbeck Capital Management, the $3.4 billion commodities hedge-fund firm led by oil trader Andy Hall, gained 3.1% in April and is up more than 11% on the year, according to investor documents.

For some big firms, the problems arose when they switched gears at the wrong time. Quantitative Investment Management LLC, a $2.7 billion firm based in Charlottesville, Va., that frequently shifts its positions based on the firm's models, flipped to shorting U.S. equities early in the month, and began posting losses midmonth as stock indexes rallied, according to an investor communication.

Adding to the firm's pain: QIM had been betting for much of the month on further appreciation for U.S. Treasurys, a haven asset whose prices dropped as stocks rose. QIM's flagship fund ended the month down about 5%, and is now 6% in the red for 2014 overall.

For at least one big fund, staying the course turned out to be the right move.

Viking Global Investors LP, a $27 billion Greenwich, Conn. firm, was down almost 4% in the first two weeks of the month in its flagship fund, in part due to poor-performing bets on tech stocks, but told investors it intended to maintain its positions and ride out the turmoil.

After dropping 3.4% in the first two weeks of April, the Nasdaq-100 tech index roared back with a 4% return in the back half of the month. Viking ended up about 0.4% for April.

>>> US Gapping down

Gapping down

In reaction to disappointing earnings/guidance/SSS: POWR -35.5% ( downgraded to Hold from Buy at Craig Hallum), MM -32.7% (multiple downgrades), GPOR -15.1%, BODY -14.9%, MCP -11%, EGY -9.3% (light volume), NPSP -9%, LQDT -9%, ERII -8.9%, DF -7.8%, TSLA -6.4%, SCMP -6.2%, ANDE -4.7%, (light volume), NICE -4.3%, NLY -4.1%, REE -3.8% (light volume), CZR-3.7%, ICPT -3.7%, REGN -3.7%, NVAX -3.5%, (light volume), CLR -2.7%, PMT -2.5%, (light volume), GTAT -2.3%, ARP -2.1%, RNDY -1.7% (light volume), WIN -1.6%, LPSN -1.5% (light volume), LCI -1.5%, VNDA -1.3%, INSM -1.2%, SUNE -1.1%, EMKR -1.1%, (light volume), FANG -1%, TWO -0.9%, SN -0.8% (light volume).

Casino/gaming names lower following reports that Macau may be limiting illegal money transfers: LVS -6.1%, MPEL -5.7% (also reported earnings), WYNN -5.3%, MGM -4.6%

Other news: CIE -5.7% ( announces $1 bln offering of convertible senior notes due 2024), FDX -0.4% ( FedEx may charge by size of packages, according to reports; also downgraded to Equal Weight from Overweight at Barclays; tgt lowered to $140 from $160) .

Analyst comments: QRE -3% (downgraded to Neutral from Outperform at Robert W. Baird; tgt lowered to $19 from $20 on lack of immediate catalysts, preferring NSLP or Legacy Reserves), CLF -0.6% (downgraded to Underperform from Mkt Perform at Bernstein)

>>> US Gapping up

Gapping up

In reaction to strong earnings/guidance/SSS: PME +31.1%, SCTY +10.7%, SFM +6.8%, COUP +6.3%, MRIN +6.1% (light volume), WEN +5.6%, JASO +5.6%, CSLT +5.5%, GMCR +5.3%, HIMX +5.3%, GTXI +4.7%, DCTH +4.6%, (light volume), BRKR +4.4%, (light volume), AVG +3.9%, (light volume), Z +3.6%, RIG +3.6%, SD +3.3%, BT +3.2%, )li CTRP +3.1%, BRDR +2.9%, HK+2.6%, APA +2.6% (light volume), CAR +2.5%, FOXA +2.4%, RATE +2.2%, (announces acquisition of Caring for $54 mln in cash), AGO +2.2%, (light volume), JONE +2.2%, (light volume), AXAS +2%, PNNT +1.7%, (light volume), KIM +1.7%, (light volume), ATLS +1.5%, (light volume), STB +1.4%, EFC +1.1%, COST +1.1%, CTL +1%, MATR +1%, (light volume), PRU +0.6%, PUK+0.6%, POZN +0.9% (light volume), MCD +0.2%.

M&A news: AZN 2.1% (Pfizer may bid a higher amount for AZN, according tor reports ), CHTP halted (Lundbeck to Acquire Chelsea Therapeutics; total potential consideration of up to USD 7.94 per share).

A few financial related names showing strength: BCS +6% (provides strategy update; to cut 14,000 jobs by end of year), NBG +3.3%, DB +1.5%, SAN +1%.

Metals/mining stocks trading higher: MT +2.9%, HMY +2.3%, PAAS +0.8%, GDX +0.6%, GLD +0.3%, GOLD +0.2% (reports Q1 metrics) .

Select oil/gas related names showing strength: SDRL +3.8%, PBR +1.2%, TOT +1%, STO +0.4%, RDS.A +0.3%.

Other news: WBAI +4.9% (reiterates that it has obtained proper approvals to operate an online sports lottery service in China), ROIC +3.5% ( ROIC to replace ACO in the S&P SmallCap 600), GRPN +2.3% (still checking), TWTR +2.1% (following positive Barron's mention; upgraded to Equal-Weight from Underweight at Morgan Stanley), RDN +1.8% (prices 15.5 mln share offering of common stock at $14.50 per share; increases size and prices $300 mln offering of senior notes), CAJ +1.5% (confirmed plans to acquire its own shares -- up to 17 mln shares of common stock), F +1% (announces $1.8 bln stock repurchase program to offset share dilution; consistent with capital strategy), BMRN +0.9% (positive MadMoney mention), GILD +0.7% ( announce $5 bln share buyback program), SODA +0.7% (following GMCR results), CREE +0.6% (increases stock buyback to $300 mln), TFM +0.2% (following SFM results).

Analyst comments: GIMO +5.4% (upgraded to Outperform from Neutral at Credit Suisse ), YELP +3.3% (Yelp upgraded to Overweight from Equal Weight at Morgan Stanley), SJM +0.7% (upgraded to Neutral from Sell at Goldman), DGX +0.6% (upgraded to Neutral from Underperform at BofA/Merrill; tgt raised to $58 from $50)

>>> US Early premarket gappers

Early premarket gappers

Gapping up: PME +19.8%, SCTY +9.5%, SFM +6.8%, COUP +6.3%, MRIN +6.1%, BCS +6%, GMCR +5.3%, HK +4.9%, DCTH +4.6%, BRKR +4.4%, AVG +3.9%, SDRL +3.8%, Z +3.6%, RIG +3.6%, ROIC +3.5%, NBG +3.3%, CTRP +3.1%, BRDR +2.9%, YELP +2.8%, CAR +2.5%, SUNE +2.5%, FOXA +2.4%, HMY +2.3%, GRPN +2.3%, JASO +2.2%, RATE +2.2%, AGO +2.2%,JONE +2.2%, AZN +2.1%, TWTR +2.1%, SD +1.8%, PNNT +1.7%, DB +1.5%, ATLS +1.5%, PBR +1.2%, LPSN +1.2%, EFC +1.1%, F +1%, CTL +1%, MATR +1%, GILD +0.7%, SODA +0.7%

Gapping down: POWR -35.5%, MM -32.7%, GPOR -15.1%, BODY -14.9%, EGY -13.8%, MCP -11%, ERII -8.9%, TSLA -6.4%, SCMP -6.2%, CIE -5.7%, ANDE -4.7%, NLY -4.1%, REE -3.8%, CZR -3.7%, ICPT -3.7%, NVAX -3.5%, PMT -2.5%, ARP -2.1%, RNDY -1.7%, MGM -1.6%, LVS -1.6%, LCI -1.5%, WYNN -1.4%, EMKR -1.1%, FANG -1%, GTAT -1%, TWO -0.9%, SN -0.8%

>>> United Utilities subject of takeover talk; LongRiver Partners mentioned as possible bidder

United Utilities subject of takeover talk; LongRiver Partners mentioned as possible bidder United Utilities, a listed UK-based water utility, was the subject of takeover speculation yesterday, 7 May, the Financial Times reported. The newspaper’s market report section did not cite a source for the speculation, but noted that water utilities in general were boosted after the UK’s shadow energy secretary downplayed the prospect that of a freeze on water prices.

Traders cited by the report mentioned speculation that LongRiver Partners, a consortium led by Borealis, might be interested in United Utilities.

Better clarity with regards to political and regulatory issues has sparked renewed hopes of takeovers in the water sector from sovereign wealth funds and infrastructure funds, the item said.

United Utilities’ share price closed 12.5p up at 816.5p in London yesterday, giving the company a market capitalisation of GBP 5.56bn (EUR 6.77bn).

http://www.ft.com/cms/s/0/3e7291e0-d608-11e3-a017-00144feabdc0.html?siteedition=uk on 07.05.2014

Source Financial Times

>>> Veolia CEO dismisses rumours of Suez Environnement merger discussions

Veolia CEO dismisses rumours of Suez Environnement merger discussions

Veolia Environnement (Veolia) CEO Antoine Frerot has dismissed speculation that the listed French utility group was in talks with competitor Suez Environnement regarding a merger, The Financial Timesreported.

Frerot said that Veolia was not in discussions regarding any deals, the item said.

The CEO added that he is not expecting any consolidation of the water and waste sector over the next 12 months, according to the report.

Veolia and Suez Environnement held exploratory discussions about a merger a number of years ago, and talk of the deal has emerged again, the item said.

Veolia’s market capitalisation currently stands at EUR 7.12bn (USD 8.67bn).

Source Financial Times

>>> Carrefour and Casino favourites to acquire Dia France; Colruyt could be interested

Carrefour and Casino favourites to acquire Dia France; Colruyt could be interested

The listed French retailer Carrefour and Casino Guichard Perrachon are understood to be favourites in the auction for Dia France, part of the listed, Spanish supermarkets group Distribuidora Internacional de Alimentacion [DIA SM], French weekly LSA reported.

The article cited a source close to Dia as saying Dia France has attracted a lot of interest, adding that the sale is expected to conclude shorty. Another French source claimed the deal could be finalised by the end of the next month.

The report noted the FO labour union published a tweet this week saying Dia France was on the verge of being sold.

According to the report, Carrefour and Casino are the last remaining potential buyers which are bidding for the entire business, while competitor Intermarche is believed to have walked out.

However, an acquisition by Casino could raise competition issues, with an expert claiming that Casino would have to sell back 100 stores at least, the article added.

Another expert said the most interesting assets of Dia France are its 300 stores operating in the southern regions of France, and its 200 outlets located in Paris and its suburbs.

Dia France, which operates 840 outlets, could be valued between EUR 150m and EUR 200m. The unit, whose assets are valued at about EUR 500m, owes a debt of EUR 200m and generated operating losses of EUR 25m in 2013.

Another unsourced report from daily Le Figaro also mentioned the Dutch retailer Colruyt as a potential buyer for Dia France.

Source LSA, Le Figaro

>>> Meda Pharmaceuticals said to have approached Darwazah family with GBP 22 per share offer for Hikma

Meda Pharmaceuticals said to have approached Darwazah family with GBP 22 per share offer for Hikma Meda Pharmaceuticals is said to have approached the Darwazah family with a GBP 22 (EUR 26.81) per share offer for Hikma Pharmaceuticals, the Daily Mail reported.

The newspaper’s market report mentioned talk that Meda had made an approach to the family, which holds a 42% stake in Hikma, but did not cite a source.

The item said an offer at GBP 22 a share would represent a GBP 4.3bn valuation for Hikma, a listed UK-based pharmaceuticals company.

The speculation grew stronger yesterday (7 May) after a senior Meda executive said the company has amassed a large budget for mergers and acquisitions, according to the report.

A market report in the Daily Express noted talk that Mylan, a listed Pennsylvania-based manufacturer of generic drugs, might be interested in acquiring Hikma.

Hikma’s share price closed 33p up at 1,620p in London yesterday, giving the UK-based company a market cap of GBP 3.21bn.

Source Daily Mail, Daily Express